{
    "clinical_study": {
        "@rank": "144596", 
        "arm_group": [
            {
                "arm_group_label": "BEMA Buprenorphine 300mcg", 
                "arm_group_type": "Experimental", 
                "description": "BEMA Buprenorphine 300mcg"
            }, 
            {
                "arm_group_label": "BEMA Buprenorphine 450mcg", 
                "arm_group_type": "Experimental", 
                "description": "BEMA Buprenorphine 450mcg"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary aim of EN3409-204 is to determine if chronic pain subjects on around the clock\n      opioids who are receiving 100 to 220 mg oral MSE can be safely transitioned on to BEMA\n      Buprenorphine at 50% of their MSE dose without inducing opioid withdrawal or reversing\n      analgesic effects."
        }, 
        "brief_title": "An Evaluation of the Tolerability of Switching Subjects on Chronic Around-the-Clock (ATC) Opioid Therapy to BEMA Buprenorphine", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Around the Clock Opioid Users", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent obtained prior to any study-related procedure being\n             performed\n\n          2. Male or non-lactating female subjects 18 to 60 years of age at time of consent\n\n          3. Female subjects who are non-pregnant on the basis of screening serum pregnancy test\n             and who are practicing abstinence or using a medically acceptable form of\n             contraception (eg, intrauterine device, hormonal birth control, or double barrier\n             method) or have been post-menopausal, biologically sterile, or surgically sterile\n             (ie, hysterectomy, bilateral oophorectomy, or tubal ligation) for more than 1 year\n\n          4. Male subjects who are practicing abstinence, surgically sterile or are using a\n             medically acceptable form of contraception\n\n          5. Subjects with a \u22656 months history of chronic pain (including peripheral neuropathic\n             pain) requiring ATC opioid therapy with \u226580 mg but \u2264220 mg MSE per day for at least\n             28 days\n\n          6. Receiving one of the following opioids ATC for \u226528 days: (i) Morphine Sulfate; (ii)\n             Oxycodone hydrochloride\n\n          7. Displays signs and symptoms of withdrawal (ie, COWS score \u22655) within 5 minutes\n             following naloxone challenge\n\n          8. Able to understand the study procedures, complete the assessment scales, and\n             communicate meaningfully with study personnel\n\n          9. Stable health, as determined by the PI, on the basis of medical history, physical\n             examination, and screening laboratory results\n\n        Exclusion Criteria:\n\n          1. Inability to meet study participation requirements, including two 2 night stays with\n             PK sampling\n\n          2. A history or current evidence of clinically significant pulmonary (eg, asthma, COPD,\n             cor pulmonale or severe bronchial asthma ), gastrointestinal, hepatic, renal,\n             hematologic, immunologic, endocrine, neurologic, oncologic or psychiatric disorder or\n             any other condition, including evidence of abnormalities on physical examination,\n             abnormal vital signs, ECG, or clinical laboratory values which in the opinion of the\n             Investigator, would jeopardize the safety of the subject or impact the validity of\n             the study results\n\n          3. Supine systolic blood pressure >180 mm Hg or <90 mm Hg or diastolic blood pressure >\n             105 mm Hg or <50 mm Hg at screening (may be repeated once)\n\n          4. COWS score greater than 4 prior to the screening naloxone challenge\n\n          5. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper\n             limits of normal (ULN) or serum creatinine >1.9 mg/dL at Screening, or any laboratory\n             abnormality which, in the opinion of the Investigator, would contraindicate study\n             participation\n\n          6. Use of monoamine oxidase inhibitors (MAOI) within 14 days of screening or during the\n             study\n\n          7. Use of any medication, nutraceutical or herbal product with CYP3A4 inhibition or\n             induction properties within the past 30 days\n\n          8. Donation of 450 mL or more of blood within 30 days prior to screening or a hemoglobin\n             value <11.0 g/dL at screening\n\n          9. Documented history of alcohol and/or substance abuse (excluding nicotine and/or\n             caffeine) within 5 years prior to screening, and/or is currently in treatment or is\n             seeking treatment for alcohol and/or substance abuse, as assessed by the Diagnostic\n             and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria (Appendix A)\n\n         10. Positive alcohol breath test at screening\n\n         11. Positive urine toxicology screen for drugs of abuse at screening\n\n         12. History of hypersensitivity, allergy, or contraindication to any opioid or clinically\n             significant intolerance to buprenorphine or naloxone\n\n         13. History of seizures, convulsions, or increased intra-cranial pressure (history of\n             pediatric febrile seizures is permitted)\n\n         14. History of significant head injury within 6 months of screening\n\n         15. Any clinically significant abnormality of the buccal mucosa which could impact drug\n             absorption\n\n         16. Participation in the treatment phase of a clinical research study involving any\n             investigational drug within 28 days (or 5 elimination half-lives, whichever is\n             longer) of screening\n\n         17. Previous participation in this clinical study or any other clinical study involving\n             BEMA Buprenorphine\n\n         18. In the Investigator's opinion at significant risk for suicidal behavior based on the\n             Columbia Suicide Severity Rating Scale (C-SSRS)\n\n         19. Hypokalemia or clinically unstable cardiac disease, including unstable atrial\n             fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active\n             myocardial ischemia\n\n         20. History of myocardial infarction\n\n         21. Corrected QT interval (QTcF) of \u2265450 milliseconds on the 12-lead ECG\n\n         22. History of long QT syndrome or a family member with this condition\n\n         23. Use of class IA antiarrhythmic medications or class III antiarrhythmic medications\n             within 14 days of screening\n\n         24. Current use of \u03b12 agonist antihypertensives (eg, clonidine), 5-HT3 antagonists (eg,\n             ondansetron), benzodiazepines, or other medications that would be anticipated to\n             confound detection of signs and symptoms of opioid withdrawal\n\n         25. Involvement in the planning and/or conduct of the study (applies to both sponsor or\n             designee staff and staff at the study sites)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871285", 
            "org_study_id": "EN3409-204"
        }, 
        "intervention": [
            {
                "arm_group_label": "BEMA Buprenorphine 300mcg", 
                "description": "Morphine Sulfate 30mg", 
                "intervention_name": "Morphine Sulfate 30mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BEMA Buprenorphine 300mcg", 
                "description": "Oxycodone 20mg", 
                "intervention_name": "Oxycodone 20mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BEMA Buprenorphine 450mcg", 
                "description": "Morphine 45mg", 
                "intervention_name": "Morphine 45mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BEMA Buprenorphine 450mcg", 
                "description": "Oxycodone 30mg", 
                "intervention_name": "Oxycodone 30mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BEMA Buprenorphine 300mcg", 
                "description": "Morphine Sulfate 15mg", 
                "intervention_name": "Morphine Sulfate 15mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BEMA Buprenorphine 300mcg", 
                "description": "Oxycodone 10mg", 
                "intervention_name": "Oxycodone 10mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BEMA Buprenorphine 450mcg", 
                "description": "Morphine Sulfate 30mg", 
                "intervention_name": "Morphine Sulfate 30mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BEMA Buprenorphine 450mcg", 
                "description": "Oxycodone 15mg", 
                "intervention_name": "Oxycodone 15mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Morphine", 
                "Oxycodone", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "ATC, Opioid, withdrawal, switch", 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Evaluation of the Tolerability of Switching Subjects on Chronic Around-the-Clock (ATC) Opioid Therapy to BEMA Buprenorphine", 
        "overall_contact": {
            "email": "salamea.monica@endo.com", 
            "last_name": "Monica Salamea, BA", 
            "phone": "484-216-7117"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\u2022\tTo evaluate the tolerability of switching to BEMA Buprenorphine, as measured by the clinical opiate withdrawal scale (COWS) scores, when opioid dependent subjects with chronic pain are switched from their stable opioid dose to approximately 50% of their stable dose compared to an estimated 50% morphine sulfate equivalent (MSE) of BEMA Buprenorphine", 
            "measure": "COWS", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871285"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the effect on the \"Pain Now\" Numeric Rating Scale (NRS) scores when opioid dependent subjects with chronic pain are switched from a stable opioid dose to 50% of their stable dose or to 50% MSE of BEMA Buprenorphine.", 
                "measure": "Pain Now", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "To evaluate other aspects of safety and tolerability of BEMA Buprenorphine when opioid dependent subjects with chronic pain are switched from a stable opioid dose to 50% of their stable dose or 50% MSE of BEMA Buprenorphine.", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Endo Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Endo Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}